论文部分内容阅读
目的探讨奥沙利铂、亚叶酸钙和氟尿嘧啶(mFOLFOX6)方案化疗联合射频消融(RFA)治疗原发性肝癌(PHC)的临床疗效。方法选取2009年9月至2015年9月间湘潭市中心医院收治的138例PHC患者,采用随机数表法分别观察组和对照组,每组69例。观察组患者采用RFA治疗1周后行mFOLFOX6化疗,对照组患者仅采用RFA治疗,比较两组近期疗效、生活质量评估及不良反应。结果治疗后,观察组患者近期总有效率为68.1%,高于对照组患者的44.9%,两组组间比较差异有统计学意义(P<0.05)。观察组患者生活质量改善情况优于对照组患者,差异有统计学意义(P<0.05),观察组患者不良反应发生率明显高于对照组,差异有统计学意义(P<0.05)。结论mFOLFOX6化疗联合RFA治疗PHC具有协同作用,能有效抑制肿瘤生长,改善患者生活质量,近期疗效显著且安全性较好。
Objective To investigate the clinical effects of oxaliplatin, leucovorin and mFOLFOX6 regimen combined with radiofrequency ablation (RFA) in the treatment of primary hepatocellular carcinoma (PHC). Methods A total of 138 patients with PHC who were admitted to Xiangtan Central Hospital from September 2009 to September 2015 were selected and randomly divided into observation group and control group with 69 cases in each group. Patients in the observation group were treated with mFOLFOX6 after 1 week of treatment with RFA. Patients in the control group were treated with RFA only. The short-term efficacy, quality of life assessment and adverse reactions were compared between the two groups. Results After treatment, the total effective rate in the observation group was 68.1%, which was higher than that in the control group (44.9%). There was significant difference between the two groups (P <0.05). The improvement of quality of life in the observation group was better than that in the control group, the difference was statistically significant (P <0.05). The incidence of adverse reactions in the observation group was significantly higher than that in the control group (P <0.05). Conclusion The combination of mFOLFOX6 chemotherapy and RFA has a synergistic effect on PHC, which can effectively inhibit tumor growth and improve the quality of life of patients with significant efficacy and safety in the near future.